TECOGEN INC. Form 8-K January 09, 2018

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): January 9, 2018 (January 4, 2018)

TECOGEN INC.

(Exact Name of Registrant as Specified in Charter)

Delaware

(State or Other Jurisdiction of Incorporation)

001-36103 04-3536131

(Commission File Number) (IRS Employer Identification No.)

45 First Avenue

Waltham, Massachusetts 02451 (Address of Principal Executive Offices) (Zip Code)

(781) 622-1120

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company b

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. "

Item 1.01 Entry Into a Material Definitive Agreement.

On January 4, 2018, Tecogen Inc., (the "Company") entered into a Research and Development Agreement (the "Agreement") with Southwest Research Institute, a Texas non-profit company ("Southwest"). The Company has engaged Southwest to work on optimizing catalyst formations applicable to the Company's Ultera emissions aftertreatment system when utilized on gasoline-fueled automobile engines. This will further the Company's goal of adapting and ultimately commercializing the Ultera process into the automotive market.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

The following exhibits relating to Item 1.01 shall be deemed to be filed with this Current Report on Form 8-K.

Exhibit No. Description

10.01 Research and Development Agreement between the Company and Southwest, dated January 4, 2018

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

TECOGEN INC.

By: /s/ Bonnie Brown

January 9, 2018 Bonnie Brown, Principal Financial & Accounting Officer